{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=33",
    "query": {
      "condition": "Developmental Defect",
      "page": 33
    },
    "page_size": 10
  },
  "pagination": {
    "page": 33,
    "page_size": 10,
    "total_count": 10802,
    "total_pages": 1081,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=34&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Developmental+Defect&page=32&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-24T20:48:35.168Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT04640142",
      "title": "Study to Evaluate the Pharmacokinetics, Efficacy, Tolerability, and Safety of Subcutaneous Human Immunoglobulin (Newnorm) in Patients With Primary Immunodeficiency Diseases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Primary Immune Deficiency"
      ],
      "interventions": [
        {
          "name": "Newnorm",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Octapharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "2 Years to 75 Years"
      },
      "enrollment_count": 50,
      "start_date": "2021-08-04",
      "completion_date": "2026-09",
      "has_results": false,
      "last_update_posted_date": "2026-08-06",
      "last_synced_at": "2026-10-24T20:48:35.168Z",
      "location_count": 10,
      "location_summary": "Irvine, California • Centennial, Colorado • Port Saint Lucie, Florida + 7 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Centennial",
          "state": "Colorado"
        },
        {
          "city": "Port Saint Lucie",
          "state": "Florida"
        },
        {
          "city": "St. Petersburg",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04640142"
    },
    {
      "nct_id": "NCT01421888",
      "title": "The NIH UNI Study: Urea Cycle Disorders, Nutrition and Immunity",
      "overall_status": "TERMINATED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Argininosuccinic Aciduria",
        "Carbamoyl-Phosphate Synthase I Deficiency",
        "Citrullinemia",
        "Ornithine Carbamoyltransferase Deficiency",
        "Hyperargininemia",
        "N-Acetylglutamate Synthase Deficiency"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "National Human Genome Research Institute (NHGRI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "99 Years",
        "sex": "ALL",
        "summary": "2 Years to 99 Years"
      },
      "enrollment_count": 4,
      "start_date": "2011-08-08",
      "completion_date": "2013-04-17",
      "has_results": false,
      "last_update_posted_date": "2019-12-09",
      "last_synced_at": "2026-10-24T20:48:35.168Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01421888"
    },
    {
      "nct_id": "NCT02636686",
      "title": "Extension Study of Drisapersen in DMD Subjects",
      "overall_status": "NO_LONGER_AVAILABLE",
      "study_type": "EXPANDED_ACCESS",
      "phases": [],
      "conditions": [
        "Duchenne Muscular Dystrophy"
      ],
      "interventions": [
        {
          "name": "Drisapersen",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "BioMarin Pharmaceutical",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "80 Years",
        "sex": "MALE",
        "summary": "5 Years to 80 Years · Male only"
      },
      "enrollment_count": null,
      "start_date": null,
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2018-01-24",
      "last_synced_at": "2026-10-24T20:48:35.168Z",
      "location_count": 1,
      "location_summary": "Baltimore, Maryland",
      "locations": [
        {
          "city": "Baltimore",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02636686"
    },
    {
      "nct_id": "NCT02246673",
      "title": "RDEA3170 and Febuxostat Combination Study in Gout Subjects",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Gout"
      ],
      "interventions": [
        {
          "name": "RDEA3170 15 mg",
          "type": "DRUG"
        },
        {
          "name": "RDEA3170 10 mg",
          "type": "DRUG"
        },
        {
          "name": "RDEA3170 2.5",
          "type": "DRUG"
        },
        {
          "name": "RDEA3170 5 mg",
          "type": "DRUG"
        },
        {
          "name": "Febuxostat 40 mg",
          "type": "DRUG"
        },
        {
          "name": "Febuxostat 80 mg",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ardea Biosciences, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 64,
      "start_date": "2014-10",
      "completion_date": "2016-02",
      "has_results": true,
      "last_update_posted_date": "2017-07-27",
      "last_synced_at": "2026-10-24T20:48:35.168Z",
      "location_count": 6,
      "location_summary": "Anaheim, California • Glendale, California • South Miami, Florida + 2 more",
      "locations": [
        {
          "city": "Anaheim",
          "state": "California"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "South Miami",
          "state": "Florida"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        },
        {
          "city": "Overland Park",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02246673"
    },
    {
      "nct_id": "NCT01723553",
      "title": "Amyloid-related Imaging Abnormalities (Microbleeds) in Atypical AD",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Atypical Alzheimers Disease",
        "Logopenic Variant of Primary Progressive Aphasia (LPA)",
        "Posterior Cortical Atrophy (PCA)"
      ],
      "interventions": [
        {
          "name": "C-11 PiB",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 27,
      "start_date": "2012-11",
      "completion_date": "2015-03",
      "has_results": false,
      "last_update_posted_date": "2015-12-21",
      "last_synced_at": "2026-10-24T20:48:35.168Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01723553"
    },
    {
      "nct_id": "NCT02110069",
      "title": "A Study to Compare Vincristine to Sirolimus for Treatment of High Risk Vascular Tumors",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kaposiform Hemangioendothelioma (KHE)",
        "Kasabach-Merritt Syndrome",
        "Tufted Angioma"
      ],
      "interventions": [
        {
          "name": "Vincristine",
          "type": "DRUG"
        },
        {
          "name": "Sirolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Boston Children's Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "31 Years",
        "sex": "ALL",
        "summary": "Up to 31 Years"
      },
      "enrollment_count": 4,
      "start_date": "2017-06-14",
      "completion_date": "2020-10-27",
      "has_results": true,
      "last_update_posted_date": "2023-09-21",
      "last_synced_at": "2026-10-24T20:48:35.168Z",
      "location_count": 7,
      "location_summary": "Palo Alto, California • Atlanta, Georgia • Baltimore, Maryland + 4 more",
      "locations": [
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cincinnati",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02110069"
    },
    {
      "nct_id": "NCT05028894",
      "title": "23andMe IPF Research Study",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Idiopathic Pulmonary Fibrosis"
      ],
      "interventions": [
        {
          "name": "No intervention",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "23andMe, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 690,
      "start_date": "2020-06-05",
      "completion_date": "2023-05-05",
      "has_results": false,
      "last_update_posted_date": "2024-12-09",
      "last_synced_at": "2026-10-24T20:48:35.168Z",
      "location_count": 1,
      "location_summary": "Sunnyvale, California",
      "locations": [
        {
          "city": "Sunnyvale",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05028894"
    },
    {
      "nct_id": "NCT03279094",
      "title": "Haploidentical Transplantation With Pre-Transplant Immunosuppressive Therapy for Patients With Sickle Cell Disease",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Sickle Cell Disease"
      ],
      "interventions": [
        {
          "name": "Hematopoietic stem cell transplantation",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "1 Year to 30 Years"
      },
      "enrollment_count": 11,
      "start_date": "2018-02-02",
      "completion_date": "2027-01-25",
      "has_results": false,
      "last_update_posted_date": "2026-05-12",
      "last_synced_at": "2026-10-24T20:48:35.168Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03279094"
    },
    {
      "nct_id": "NCT03108066",
      "title": "MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "VHL Gene Mutation",
        "VHL",
        "VHL Syndrome",
        "VHL Gene Inactivation",
        "Von Hippel",
        "Von Hippel-Lindau Disease",
        "Von Hippel's Disease",
        "Von Hippel-Lindau Syndrome, Modifiers of",
        "Clear Cell Renal Cell Carcinoma",
        "Clear Cell RCC",
        "ccRCC"
      ],
      "interventions": [
        {
          "name": "MK-3795",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 4,
      "start_date": "2017-04-24",
      "completion_date": "2023-09-27",
      "has_results": true,
      "last_update_posted_date": "2024-09-24",
      "last_synced_at": "2026-10-24T20:48:35.168Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03108066"
    },
    {
      "nct_id": "NCT05317637",
      "title": "Cardiopulmonary Outcomes in Osteogenesis Imperfecta: BBD7708",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Osteogenesis Imperfecta"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "Baylor College of Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": null,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2022-08-01",
      "completion_date": "2027-09-01",
      "has_results": false,
      "last_update_posted_date": "2026-03-02",
      "last_synced_at": "2026-10-24T20:48:35.168Z",
      "location_count": 3,
      "location_summary": "Los Angeles, California • Baltimore, Maryland • New York, New York",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05317637"
    }
  ]
}